# A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass

> **NCT04003467** · PHASE2 · COMPLETED · sponsor: **Entera Bio Ltd.** · enrollment: 161 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** EBP05
- **DRUG:** Placebo of EBP05

## Key facts

- **NCT ID:** NCT04003467
- **Lead sponsor:** Entera Bio Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-30
- **Primary completion:** 2021-04-27
- **Final completion:** 2021-05-11
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2021-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04003467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04003467, "A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04003467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*